SABS - SAB Biotherapeutics, Inc.
3.52
-0.280 -7.955%
Share volume: 555,970
Last Updated: 04-24-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.22%
PREVIOUS CLOSE
CHG
CHG%
$3.80
-0.28
-0.07%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-20-2024 | 08-08-2024 | 11-06-2024 | 05-09-2025 | 11-13-2025 | 03-09-2026 | |
| Assets | |||||||
| Total Assets | 71.371 M | 61.892 M | 53.797 M | 38.120 M | 183.448 M | 172.810 M | |
| Current Assets | 46.951 M | 39.580 M | 32.537 M | 16.297 M | 113.277 M | 101.053 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 2.701 M | 224.924 K | 97.047 K | 21.386 K | 559.954 K | 946.781 K | |
| Short Term Investments | 2.701 M | 20.084 M | 21.229 M | 7.210 M | 81.456 M | 86.090 M | |
| Total Receivables | 193.232 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 44.057 M | 17.242 M | 9.171 M | 5.640 M | 29.425 M | 10.503 M | |
| Total Non-current Assets | 24.420 M | 0.000 | 0.000 | 0.000 | 50.609 M | 46.893 M | |
| Property Plant Equipment | 17.903 M | 16.921 M | 16.077 M | 14.611 M | 13.114 M | 13.306 M | |
| Other Assets | 5.282 M | 5.390 M | 5.184 M | 7.212 M | 57.057 M | 58.451 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||
| Total Liabilities and shareholders’ equity | 71.371 M | 61.892 M | 53.797 M | 38.120 M | 183.448 M | 172.810 M | |
| Total liabilities | 18.549 M | 15.772 M | 16.895 M | 16.713 M | 18.374 M | 21.316 M | |
| Total current liabilities | 8.305 M | 7.552 M | 8.816 M | 9.653 M | 10.793 M | 10.681 M | |
| Accounts Payable | 1.240 M | 6.226 M | 8.177 M | 8.576 M | 9.805 M | 9.730 M | |
| Other liabilities | 6.306 M | 8.220 M | 8.078 M | 7.059 M | 7.581 M | 10.634 M | |
| Current long term debt | 1.513 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 3.938 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 6.306 M | 8.220 M | 8.078 M | 7.059 M | 7.581 M | 10.634 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 52.822 M | 46.120 M | 36.903 M | 21.407 M | 165.074 M | 151.494 M | |
| Common stock | 9.242 M | 154.097 M | 155.146 M | 156.406 M | 264.559 M | 267.724 M | |
| Retained earnings | -95.089 M | -102.425 M | -112.774 M | -129.366 M | -94.034 M | -110.895 M |